Wird geladen...
2493. Real-World Utilization of Ibalizumab (IBA) Without an Optimized Background Regimen (OBT)
BACKGROUND: It is difficult to treat multidrug-resistant (MDR) human immunodeficiency virus (HIV). Trogarzo® (ibalizumab) a novel monoclonal antibody was approved in 2018 for heavily treatment-experienced HIV patients. Data support IBA use with at least one fully active agent, an OBR. Real-world IBA...
Gespeichert in:
| Veröffentlicht in: | Open Forum Infect Dis |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6809681/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.2171 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|